Page 300 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 15 Molecular/Targeted Therapy of Cancer 279

274. Ridolfi L, Petrini M, Granato AM, et al.: Low-dose temozolo- 292. Custead MR, Weng HY, Childress MO: Retrospective compari-
mide before dendritic-cell vaccination reduces (specifically) son of three doses of metronomic chlorambucil for tolerability and
CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma efficacy in dogs with spontaneous cancer, Vet Comp Oncol 15:808–
VetBooks.ir 275. Denies S, Cicchelero L, de Rooster H, et al.: Immunological and 293. Tripp CD, Fidel J, Anderson CL, et al.: Tolerability of metronomic
819, 2017.
patients, J Transl Med 11:135, 2013.
angiogenic markers during metronomic temozolomide and cyclo-
phosphamide in canine cancer patients, Vet Comp Oncol 15:594– administration of lomustine in dogs with cancer, J Vet Intern Med
25:278–284, 2011.
605, 2017. 294. Rasmussen RM, Kurzman ID, Biller BJ, et al.: Phase I lead-in and
276. Cancedda S, Rohrer Bley C, Aresu L, et al.: Efficacy and subsequent randomized trial assessing safety and modulation of
side effects of radiation therapy in comparison with radia- regulatory T cell numbers following a maximally tolerated dose
tion therapy and temozolomide in the treatment of mea- doxorubicin and metronomic dose cyclophosphamide combina-
surable canine malignant melanoma, Vet Comp Oncol 14: tion chemotherapy protocol in tumour-bearing dogs, Vet Comp
e146–e157, 2016. Oncol 15:421–430, 2017.
277. Treggiari E, Elliott JW, Baines SJ, et al.: Temozolomide alone 295. Cancedda S, Marconato L, Meier V, et al.: Hypofractionated
or in combination with doxorubicin as a rescue agent in 37 radiotherapy for macroscopic canine soft tissue sarcoma: a retro-
cases of canine multicentric lymphoma, Vet Comp Oncol 16: spective study of 50 cases treated with a 5 x 6 Gy protocol with
194–201, 2018. or without metronomic chemotherapy, Vet Radiol Ultrasound 57:
278. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for 75–83, 2016.
cancer dormancy, Nat Rev Cancer 7:834–846, 2007. 296. Duffy ME, Anderson CL, Choy K, et al.: Metronomic administra-
279. Calabrese C, Poppleton H, Kocak M, et al.: A perivascular niche for tion of lomustine following palliative radiation therapy for appen-
brain tumor stem cells, Cancer Cell 11:69–82, 2007. dicular osteosarcoma in dogs, Can Vet J 59:136–142, 2018.
280. Folkins C, Man S, Xu P, et al.: Anticancer therapies combining 297. Cicchelero L, Denies S, Vanderperren K, et al.: Immunological,
antiangiogenic and tumor cell cytotoxic effects reduce the tumor anti-angiogenic and clinical effects of intratumoral interleukin 12
stem-like cell fraction in glioma xenograft tumors, Cancer Res electrogene therapy combined with metronomic cyclophospha-
67:3560–3564, 2007. mide in dogs with spontaneous cancer: a pilot study, Cancer Lett
281. Martin-Padura I, Marighetti P, Agliano A, et al.: Residual dormant 400:205–218, 2017.
cancer stem-cell foci are responsible for tumor relapse after anti- 298. Shih T, Lindley C: Bevacizumab: an angiogenesis inhibitor for the
angiogenic metronomic therapy in hepatocellular carcinoma xeno- treatment of solid malignancies, Clin Ther 28:1779–1802, 2006.
grafts, Lab Invest 92:952–966, 2012. 299. London CA: Tyrosine kinase inhibitors in veterinary medicine, Top
282. Colleoni M, Rocca A, Sandri MT, et al.: Low-dose oral methotrex- Companion Anim Med 24:106–112, 2009.
ate and cyclophosphamide in metastatic breast cancer: antitumor 300. Tjostheim SS, Stepien RL, Markovic LE, et al.: Effects of toceranib
activity and correlation with vascular endothelial growth factor lev- phosphate on systolic blood pressure and proteinuria in dogs, J Vet
els, Ann Oncol 13:73–80, 2002. Intern Med 30:951–957, 2016.
283. Lien K, Georgsdottir S, Sivanathan L, et al.: Low-dose metro- 301. Piscoya SL, Hume KR, Balkman CE: A retrospective study of pro-
nomic chemotherapy: a systematic literature analysis, Eur J Cancer teinuria in dogs receiving toceranib phosphate, Can Vet J 59:611–
49:3387–3395, 2013. 616, 2018.
284. Parikh PM, Hingmire SS, Deshmukh CD: Selected current data 302. Hume KR, Rizzo VL, Cawley JR, et al.: Effects of toceranib phos-
on metronomic therapy (and its promise) from India, South Asian J phate on the hypothalamic-pituitary-thyroid axis in tumor-bearing
Cancer 5:37–47, 2016. dogs, J Vet Intern Med 32:377–383, 2018.
285. Pramanik R, Agarwala S, Gupta YK, et al.: Metronomic che- 303. Charney SC, Bergman PJ, Hohenhaus AE, et al.: Risk factors
motherapy vs best supportive care in progressive pediatric solid for sterile hemorrhagic cystitis in dogs with lymphoma receiving
malignant tumors: a randomized clinical trial, JAMA Oncol 3: cyclophosphamide with or without concurrent administration
1222–1227, 2017. of furosemide: 216 cases (1990-1996), J Am Vet Med Assoc 222:
286. Lana S, U’Ren L, Plaza S, et al.: Continuous low-dose oral chemo- 1388–1393, 2003.
therapy for adjuvant therapy of splenic hemangiosarcoma in dogs, 304. Matsuyama A, Woods JP, Mutsaers AJ: Evaluation of toxicity of
J Vet Intern Med 21:764–769, 2007. a chronic alternate day metronomic cyclophosphamide chemo-
287. Wendelburg KM, Price LL, Burgess KE, et al.: Survival time of therapy protocol in dogs with naturally occurring cancer, Can Vet J
dogs with splenic hemangiosarcoma treated by splenectomy with 58:51–55, 2017.
or without adjuvant chemotherapy: 208 cases (2001-2012), J Am 305. Gaeta R, Brown D, Cohen R, et al.: Risk factors for development
Vet Med Assoc 247:393–403, 2015. of sterile haemorrhagic cystitis in canine lymphoma patients receiv-
288. Matsuyama A, Poirier VJ, Mantovani F, et al.: Adjuvant doxo- ing oral cyclophosphamide: a case-control study, Vet Comp Oncol
rubicin with or without metronomic cyclophosphamide for 12:277–286, 2014.
canine splenic hemangiosarcoma, J Am Anim Hosp Assoc 53: 306. Setyo L, Ma M, Bunn T, et al.: Furosemide for prevention of
304–312, 2017. cyclophosphamide-associated sterile haemorrhagic cystitis in dogs
289. Matsuyama A, Schott CR, Wood GA, et al.: Evaluation of metro- receiving metronomic low-dose oral cyclophosphamide, Vet Comp
nomic cyclophosphamide chemotherapy as maintenance treatment Oncol 15:1468–1478, 2017.
for dogs with appendicular osteosarcoma following limb amputa- 307. Chan CM, Frimberger AE, Moore AS: Incidence of sterile hemor-
tion and carboplatin chemotherapy, J Am Vet Med Assoc 252:1377– rhagic cystitis in tumor-bearing dogs concurrently treated with oral
1383, 2018. metronomic cyclophosphamide chemotherapy and furosemide: 55
290. London CA, Gardner HL, Mathie T, et al.: Impact of toceranib/ cases (2009-2015), J Am Vet Med Assoc 249:1408–1414, 2016.
piroxicam/cyclophosphamide maintenance therapy on outcome of 308. Kerbel RS: A cancer therapy resistant to resistance, Nature
dogs with appendicular osteosarcoma following amputation and 390:335–336, 1997.
carboplatin chemotherapy: a multi-institutional study, PLoS One 309. Ebos JM, Lee CR, Kerbel RS: Tumor and host-mediated pathways
10:e0124889, 2015. of resistance and disease progression in response to antiangiogenic
291. Bentley RT, Thomovsky SA, Miller MA, et al.: Canine therapy, Clin Cancer Res 15:5020–5025, 2009.
(pet dog) tumor microsurgery and intratumoral concentra- 310. Paez-Ribes M, Allen E, Hudock J, et al.: Antiangiogenic
tion and safety of metronomic chlorambucil for spontane- therapy elicits malignant progression of tumors to increased
ous glioma: a phase I clinical trial, World Neurosurg 116: local invasion and distant metastasis, Cancer Cell 15:
E534–E542, 2018. 220–231, 2009.